[ Checkmate Pharmaceuticals raises $27M in Series B ]

Checkmate Pharmaceuticals has raised $27 million in Series B funding.

Founded in 2015, Checkmate Pharmaceuticals  is developing a new approach for cancer immunotherapy that activates the immune system to recognize and kill tumor cells in the body.

Proceeds from the financing will be used to further advance clinical development of CMP-001, a first-in-class CpG-A oligonucleotide that activates the innate immune system via Toll-like receptor 9 (TLR9), and which is currently being studied in a Phase 1b trial in combination with pembrolizumab in primary refractory melanoma patients who have either progressed on or failed to respond to anti-PD-1 therapy.

Funding  Series B
Founded  2015
Country  USA
City  Cambridge, Massachusetts
Founder / CEO  Arthur Krieg
Deal Size  $27M
Investors  F-Prime Capital Partners
 Sofinnova Ventures
 venBio Partners
 Auspitz
Previous Investors  Sofinnova Ventures
 venBio Partners